Patents Assigned to PROTEA BIOPHARMA N.V.
  • Patent number: 8916535
    Abstract: The invention relates to the therapeutic uses of 2?,5?-oligoadenylate derivative compounds, more particularly for the treatment of chronic fatigue syndrome (CFS) and in the treatment of infection by a gamma-retrovirus.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: December 23, 2014
    Assignee: Protea Biopharma N.V.
    Inventors: Christiaan Roelant, Kenny De Meirleir
  • Publication number: 20130237492
    Abstract: The invention relates to the therapeutic uses of 2?,5?-oligoadenylate derivative compounds, more particularly for the treatment of chronic fatigue syndrome (CFS) and in the treatment of infection by a gamma-retrovirus.
    Type: Application
    Filed: November 10, 2011
    Publication date: September 12, 2013
    Applicant: PROTEA BIOPHARMA N.V.
    Inventors: Christiaan Roelant, Kenny De Meirleir
  • Publication number: 20120077278
    Abstract: The invention provides methods and kits for detecting metabolites in a body fluid by contacting a sample of the body fluid with at least one reducible dye at a pH-value which is higher than the pKa-value of the reducible dye, whereby a color change resulting from reduction of the reducible dye is indicative of the presence of metabolites in the body fluid. The methods and kits are of use in the detection and monitoring of disease conditions.
    Type: Application
    Filed: June 8, 2009
    Publication date: March 29, 2012
    Applicant: Protea Biopharma N.V.
    Inventors: Christiaan Roelant, Kenny De Meirleir
  • Publication number: 20120015390
    Abstract: The invention relates to methods and tools for detecting and treating patients suffering from aberrant prion functioning or Aberrant Prion Disease (APD), methods for determining the presence of aberrant prion functioning-inducing agents in a sample and to methods for determining the appropriate therapy for a patient having symptoms of aberrant prion functioning based on detecting aberrant NADH oxidase activity.
    Type: Application
    Filed: March 26, 2010
    Publication date: January 19, 2012
    Applicant: PROTEA BIOPHARMA N.V.
    Inventors: Christiaan Roelant, Kenny De Meirleir